March 5, 2018 06:02 AM EST
Financing

Gene edit­ing ex­pert Ho­mol­o­gy de­tails the num­bers in its back-end­ed $1B No­var­tis deal, files for $100M IPO

John Carroll

Editor & Founder

Late Fri­day Ho­mol­o­gy Med­i­cines joined the list of biotechs crowd­ing in­to a hot IPO mar­ket, fil­ing for a $100 mil­lion of­fer­ing. And we got a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times